abrdn plc Purchases Shares of 484,666 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

abrdn plc purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 484,666 shares of the biopharmaceutical company’s stock, valued at approximately $10,115,000. abrdn plc owned 0.41% of Catalyst Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after purchasing an additional 151,495 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock valued at $23,215,000 after acquiring an additional 50,804 shares during the last quarter. JPMorgan Chase & Co. raised its position in Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares in the last quarter. Jane Street Group LLC lifted its stake in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 146.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock valued at $7,285,000 after purchasing an additional 217,956 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 in the last three months. Insiders own 11.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on CPRX. Stephens started coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Robert W. Baird started coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $28.00 target price for the company. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Bank of America reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $32.25.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $22.90 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.12 and a 52 week high of $24.64. The firm has a market cap of $2.73 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80. The firm’s fifty day moving average is $22.07 and its 200-day moving average is $20.87.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.